All Stories

  1. The calcimimetic etelcalcetide attenuates pressure overload–induced cardiac hypertrophy in rats with and without chronic kidney disease
  2. Renoprotective Effects of Goreisan via Modulation of RAAS Activity, Oxidative Stress, and AQP2 Trafficking in a Rat Model of Nephrotic Syndrome
  3. Renoprotective effects of SGLT2 inhibitors in patients with Fabry disease
  4. Comparative analysis of plasma BNP and NT-proBNP levels, and NT-proBNP/BNP ratio in patients with chronic kidney disease
  5. Patient characteristics modify the association between changes in mineral metabolism parameters and mortality in a nationwide hemodialysis cohort study
  6. The benefit of reduced serum phosphate levels depends on patient characteristics: a nationwide prospective cohort study
  7. Clinicopathological characteristics of neural epidermal growth factor-like 1 protein-associated membranous glomerulonephritis
  8. Immunohistological analysis reveals IgG1-dominant immunophenotype of tubulointerstitial nephritis unassociated with IgG4-related diseases
  9. Unravelling the Complexities of Myocardial Injury in Patients with Chronic Kidney Disease
  10. Association of abnormalities in electrocardiography and ultrasonic echocardiography with the occurrence of cardiovascular disease in patients with advanced chronic kidney disease
  11. Exploring the implications of blocking renin-angiotensin-aldosterone system and fibroblast growth factor 23 in early left ventricular hypertrophy without chronic kidney disease
  12. Clinical Implication of Consistently Strict Phosphate Control for Coronary and Valvular Calcification in Incident Patients Undergoing Hemodialysis
  13. Survival benefit of living donor kidney transplantation in patients on hemodialysis
  14. Hypocalcemia and cardiovascular mortality in cinacalcet users
  15. Investigation of bone mineral density and the changes by enzyme replacement therapy in patients with Fabry disease
  16. Renal protective effects of astragalus root in rat models of chronic kidney disease
  17. Not baseline but time-dependent erythropoiesis-stimulating agent responsiveness predicts cardiovascular disease in hemodialysis patients receiving epoetin beta pegol: A multicenter prospective PARAMOUNT-HD Study
  18. Comparison of two protocols for steroid pulse therapy in patients with IgA nephropathy: a retrospective observational study
  19. Clinical value of serum cholinesterase levels in Nephrotic syndrome: an observational study
  20. Screening for Fabry disease among male patients on hemodialysis in Awaji Island
  21. Detecting MUC1 Variants in Patients Clinicopathologically Diagnosed With Having Autosomal Dominant Tubulointerstitial Kidney Disease
  22. Statin Use Influence on the Occurrence of Acute Kidney Injury in Patients with Peripheral Arterial Disease
  23. Changes of FGF23 and the Renin-Angiotensin-System in Male Mouse Models of Chronic Kidney Disease and Cardiac Hypertrophy
  24. Beneficial screening of Fabry disease in patients with hypohidrosis
  25. X-chromosome inactivation patterns in females with Fabry disease examined by both ultra-deep RNA sequencing and methylation-dependent assay
  26. optimal phosphate in dialysis patients
  27. Influence of oxidative stress on vascular calcification in the setting of coexisting chronic kidney disease and diabetes mellitus
  28. Evaluation of aortic calcification using a three-dimensional volume-rendering method in patients with end-stage kidney disease
  29. Changes in blood pressure during treatment with the tyrosine kinase inhibitor lenvatinib
  30. Relationship between parathyroid hormone and renin–angiotensin–aldosterone system in hemodialysis patients with secondary hyperparathyroidism
  31. Histological changes of a kidney in a recipient who received an allograft from a patient with Fabry disease
  32. Pregnant Patient on Hemodialysis Who Showed Remarkable Improvement of Severe Hyperparathyroidism by Strict Serum Phosphorus Control
  33. Comparison of the effects of lanthanum carbonate and calcium carbonate on the progression of cardiac valvular calcification after initiation of hemodialysis
  34. Changes in the whole/intact parathyroid hormone ratio and their clinical implications in patients with chronic kidney disease
  35. Effects of lanthanum carbonate on bone markers and bone mineral density in incident hemodialysis patients
  36. One‐year impact of kidney transplantation on cardiac abnormalities and blood pressure in hemodialysis patients
  37. Characteristics of coronary artery disease in chronic kidney disease
  38. Changes in serum and intracardiac fibroblast growth factor 23 during the progression of left ventricular hypertrophy in hypertensive model rats
  39. Essential points from Evidence-based Clinical Practice Guidelines for Chronic Kidney Disease 2018
  40. Multicentre cross-sectional study for bone-articular lesions associated with dialysis related amyloidosis in Japan
  41. Role of Uremic Toxins for Kidney, Cardiovascular, and Bone Dysfunction
  42. Association between Parathyroid Hormone and Cardiovascular Disease
  43. Rationale, design, and characteristics of a trial to evaluate the new phosphate iron-based binder sucroferric oxyhydroxide in dialysis patients with the goal of advancing the practice of E.B.M. (EPISODE)
  44. Newly Developed Rat Model of Chronic Kidney Disease–Mineral Bone Disorder
  45. Effects of Lanthanum Carbonate on Coronary Artery Calcification and Cardiac Abnormalities After Initiating Hemodialysis
  46. Hypertension Induced by Tyrosine-Kinase Inhibitors for the Treatment of Renal Cell Carcinoma in Hemodialysis Patients: A Single-Center Experience and Review of the Literature
  47. A case of fibrillary glomerulonephritis with fibril deposition in the arteriolar wall and a family history of renal disease
  48. Relationship between cardiac calcification and left ventricular hypertrophy in patients with chronic kidney disease at hemodialysis initiation
  49. Comparison of the effects of novel vitamin D receptor analog VS-105 and paricalcitol on chronic kidney disease-mineral bone disorder in an experimental model of chronic kidney disease
  50. Mineral metabolism and cardiovascular disease in CKD
  51. Incidence and Risk Factors of Persistent Hyperparathyroidism After Kidney Transplantation
  52. The Effects of Plasma Exchange on Severe Vasculitis with Diffuse Alveolar Hemorrhage
  53. Serum FGF23 levels may not be associated with serum phosphate and 1,25-dihydroxyvitamin D levels in patients with Fanconi syndrome–induced hypophosphatemia
  54. A clinical evaluation of renal amyloidosis in the Japan renal biopsy registry: a cross-sectional study
  55. Riser pattern is a predictor of kidney mortality among patients with chronic kidney disease
  56. Two Cases of Hypophosphatemia with Increased Renal Phosphate Excretion in Legionella Pneumonia
  57. Anti-oxidative effect of AST-120 on kidney injury after myocardial infarction
  58. Relationship Between Type of Hypertension and Renal Arteriolosclerosis in Chronic Glomerular Disease
  59. The Vitamin D Receptor Activator Maxacalcitol Provides Cardioprotective Effects in Diabetes Mellitus
  60. Anti-oxidative effect of theβ-blocker carvedilol on diabetic nephropathy in non-obese type 2 diabetic rats
  61. Pre-Transplant Erythropoiesis-Stimulating Agent Hypo-Responsiveness and Post-Transplant Anemia
  62. 22-Oxacalcitriol attenuates bone loss in nonobese type 2 diabetes
  63. Effect of cinacalcet cessation on hyperparathyroidism in kidney transcaplant patients after long-term dialysis therapy
  64. Clinical Characteristics of Very Elderly Patients at Hemodialysis Initiation
  65. Elevated Expression of Pentraxin 3 in Anti-neutrophil Cytoplasmic Antibody-associated Glomerulonephritis with Normal Serum C-reactive Protein
  66. Dietary phosphorus restriction by a standard low-protein diet decreased serum fibroblast growth factor 23 levels in patients with early and advanced stage chronic kidney disease
  67. Renin-Angiotensin System Inhibitors Reduce Serum Asymmetric Dimethylarginine Levels and Oxidative Stress in Normotensive Patients with Chronic Kidney Disease
  68. A case of parathyroid adenoma adjacent to the thoracic spine in a hemodialysis patient
  69. Marked Elevation of Serum Hyaluronan Levels in Collagenofibrotic Glomerulopathy
  70. Vitamin D Activates the Nrf2-Keap1 Antioxidant Pathway and Ameliorates Nephropathy in Diabetic Rats
  71. Clinical Practice Guideline for the Management of Chronic Kidney Disease-Mineral and Bone Disorder
  72. Another role for nephrologists in disaster medicine
  73. Anti-Oxidative Effect of Vitamin D Analog on Incipient Vascular Lesion in Non-Obese Type 2 Diabetic Rats
  74. Parathyroid Enlargement at Dialysis Initiation in Patients With Chronic Kidney Diseases
  75. Association between AST-120 and abdominal aortic calcification in predialysis patients with chronic kidney disease
  76. Effect of enzyme replacement therapy on serum asymmetric dimethylarginine levels, coronary flow reserve and left ventricular hypertrophy in patients with Fabry disease
  77. Japanese Society for Dialysis Therapy Guidelines for Management of Cardiovascular Diseases in Patients on Chronic Hemodialysis
  78. Composition and plaque patterns of coronary culprit lesions and clinical characteristics of patients with chronic kidney disease
  79. Mineral and bone disease - CKD 1-5
  80. Interpretation of the Association between Beta-Blockers and Hip/Femur Fracture
  81. Successful treatment of progressive renal injury due to granulomatous tubulointerstitial nephritis with uveitis
  82. CKD / Mineral bone disease
  83. Progression & risk factors CKD 1-5 (1)
  84. Bone disease in CKD 1-5
  85. Comparison between Whole and Intact Parathyroid Hormone Assays
  86. Clinical Efficacy and Cost-Effectiveness of Lanthanum Carbonate as Second-Line Therapy in Hemodialysis Patients in Japan
  87. Uremic Toxins and Oral Adsorbents
  88. Role of Oxidative Stress and Indoxyl Sulfate in Progression of Cardiovascular Disease in Chronic Kidney Disease
  89. Clinical Characteristics and Cardiovascular Outcomes of Hemodialysis Patients with Atrial Fibrillation: A Prospective Follow-Up Study
  90. Effects of AST-120 on Left Ventricular Mass in Predialysis Patients
  91. Carvedilol Ameliorates Low-Turnover Bone Disease in Non-Obese Type 2 Diabetes
  92. Effect of Intravenous Saccharated Ferric Oxide on Serum FGF23 and Mineral Metabolism in Hemodialysis Patients
  93. The effects of the receptor for advanced glycation end products (RAGE) on bone metabolism under physiological and diabetic conditions
  94. Coronary Plaque Morphology Using Virtual Histology-Intravascular Ultrasound Analysis in Hemodialysis Patients
  95. Homocysteine and folic acid levels in hemodialysis patients treated with sevelamer hydrochloride
  96. Association Between Indoxyl Sulfate and Skeletal Resistance in Hemodialysis Patients
  97. Contrast-induced ultrasonography with Levovist in a case of exercise-induced acute kidney injury without rhabdomyolysis
  98. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients
  99. Oxidative and Nitrosative Stress and Progression of Diabetic Nephropathy in Type 2 Diabetes
  100. Marked increase in bone formation markers after cinacalcet treatment by mechanisms distinct from hungry bone syndrome in a haemodialysis patient
  101. Role of oxidative stress in diabetic bone disorder
  102. Thioredoxin-1 overexpression in transgenic mice attenuates streptozotocin-induced diabetic osteopenia: A novel role of oxidative stress and therapeutic implications
  103. Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress
  104. Prevalence and Cardiovascular Features of Japanese Hemodialysis Patients with Fabry Disease
  105. The whole-PTH/intact-PTH ratio is a useful predictor of severity of secondary hyperparathyroidism
  106. Putative Role of Asymmetric Dimethylarginine in Microvascular Disease of Kidney and Heart in Hypertensive Patients
  107. Serum Pro-hepcidin as an Indicator of Iron Status in Dialysis Patients
  108. Bone formation in spontaneously diabetic Torii-newly established model of non-obese type 2 diabetes rats
  109. Putative Role of Endothelial Lipase in Dialysis Patients with Hypoalbuminemia and Inflammation
  110. Histomorphometric analysis of diabetic osteopenia in streptozotocin-induced diabetic mice: A possible role of oxidative stress
  111. Tako-tsubo Cardiomyopathy Associated with Brain Metastasis of Seminoma in a Patient with Chronic Kidney Disease
  112. Relationship between Parathyroid Hormone and Cardiac Abnormalities in Chronic Dialysis Patients
  113. 透析患者における心房細動の臨床的特徴
  114. Regulation of parathyroid function in chronic kidney disease (CKD)
  115. Relationship between renal artery stenosis and intrarenal damage in autopsy subjects with stroke
  116. Normalization of reversed bio-intact-PTH(1-84)/intact- PTH ratio after parathyroidectomy in a patient with severe secondary hyperparathyroidism
  117. Clinical Implications of Assessing Coronary Flow Velocity Reserve and Plasma Endothelin-1 in Hypertensive Patients
  118. Primary Aldosteronism Combined With Preclinical Cushing's Syndrome in an Elderly Patient
  119. Plasma asymmetric dimethylarginine and coronary and peripheral endothelial dysfunction in hypertensive patients
  120. 1065-176 Role of endothelin-1 and coronary flow reserve in hypertensive patients without coronary artery disease
  121. Carotid Intima-Media Thickness Is Correlated with Impairment of Coronary Flow Reserve in Hypertensive Patients without Coronary Artery Disease
  122. Budd-Chiari syndrome incidentally found by an abnormal shadow on chest X-ray.